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IN a previous paper (Hartveit, 1962) the production of immunity to Ehrlich's
ascites carcinoma by means of the subcutaneous injection of the same tumour
combined with Freund's adjuvant was studied. In the course ofthat experiment
some further points arose. Firstly, to what extent did the combination with
Freund's adjuvant damage the tumour cells? This will be reflected in the sur-
vival time of the mice and is discussed in part (a) of this paper. Secondly, a
marked non-specific immune reaction was noticed in female mice following the
subcutaneous injection of adjuvant alone. Would this reaction be influenced
by a time interval between the subcutaneous and the intraperitoneal injection?
This is discussed in part (b). Thirdly, it was noticed that haemolysis occurred
in the tumour ascites in some of the mice. This was not mentioned previously
and will now be presented in detail in part (c) of this paper together with the
corresponding findings in part (b).
It will be noted that the experimental material concerned here is that used
in the previous experiment (Harveit, 1962). The composition of the material
and the treatment given are summarized in Table I, which also shows the
additional treatment given to the mice in groups 1 and 4 in the experiment
reported in part (b) of this paper.
TABLE I.-The Composition of the Experimental Material and the Treatment given
in the Different Groups. (15 Male and 15 Female Mice in Each Group)
Route of injection
Subcutaneous Intraperitoneal
Group (day 1)
1 . Nil EAC (day 30)
2 . Nil EAC (day 1)
3 . FA + EAC Nil
4 . FA + saline EAC (day 30)
5 EAC + saline Nil
6 FA +EAC EAC (day 1)
7 . FA + saline EAC (day 1)
8 . EAC + saline EAC (day 1)
FA = Freund's adjuvant. EAC - Ehrlich's ascites carcinoma.
The following experiments were carried out:
(a) The Survival Time of Mice following the Subcutaneous Injection of Ehrlich's
Ascites Carcinoma and Freund's Adjuvant
The two control groups with which we are concerned here are group 3, in
which the mice were given a mixture of Freund's adjuvant and Ehrlich's ascitesF. HARTVEIT
carcinoma subcutaneously, and its control group 5 in which they were given
tumour alone (Table I). Comparison of the survival time in these two groups
should establish the extent to which the tumour was injured by its combination
with Freund's adjuvant.
Material and methods
For a detailed description of these the reader is referred to the original paper
(Hartveit, 1962) and to Table I of this paper. To summarize: Each group
contained 15 male and 15 female mice. The mice in group 3 were each given one
subcutaneous injection of a mixture of Ehrlich's ascites carcinoma and Freund's
adjuvant, while those in group 5 each received one subcutaneous injection con-
taining the same number oftumour cells as those in group 3. The tumour came
from the same source for both groups and, with the exception of the emulsifying
process used before injection in group 3, was handled in the same way.
The mice were then examined weekly for the presence of subcutaneous tumour
and any growth present was measured. The survival time was recorded in days.
Results
Tumour nodules occurred at the site of the subcutaneous injection in all
animals. At one week there was little difference in the mean tumour diameter
in groups 3 and 5 (9.7 mm. ± 2*1 and 9*2 mm. ± 3*9, respectively). By three
weeks every tumour had reached at least 1 cm. in diameter (i.e. double the size
of the nodules found on injection of adjuvant alone in females). Thereafter
the tumours regressed in two animals in each group; in 2 females in group 3
and in 1 male and 1 female in group 5. These four mice were alive without sign
of tumour one month after all the rest were dead. They were excluded from the
survival time calculations. The remaining animals died with actively growing
tumours.
Table II shows the mean survival time ofthese mice, with the SD ofthis mean,
the SE of the difference between the female and the male means and its P value.
It will be seen that the mean survival time ofthe animals of the same sex in both
groups was approximately the same, andthat the marked sex difference (0001>P)
occurred in both groups.
TABLE II.-The Mean Survival Time in Days (x) of Mice with Subcutaneous
Ehrlich Ascites Carcinoma and Freund's Adjuvant (Group 3) Compared to that
of Mice with Subcutaneous Ehrlich Ascites Carcinoma Alone (Group 5), Giving
the Sex and Number of the Mice, the Mean Survival Time and SD, the SE of
the Sex Difference in Means and its P value
S.E.
Group Sex Number x S.D.x (Fe -xC) P
3 CT 15 .48-5 .16*4 4 7 001>P y 13*/* 78 7 24*4 4 . OvO1>P
5 CT 14* 49.3 13-45 44 -0
9 . 14* 803 31.65f 4*48 . O.OO1>P
* One mouse survived, see text.
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Discussion
The number of cells injured or killed during the emulsifying process undergone
by the tumour cells in group 3 does not appear to have affected the survival time
of the mice, which is almost identical to that of the controls which were given
the same dose of untreated tumour. It may be, however, that a large majority
of the cells were killed and that these dead cells exerted the well known XYZ
effect (Casey, Hatherway and Casey, 1956) on those remaining. This could offset
the reduced tumour cell dosage and bring the survival time back in line with that
in group 5. In any case, the assumption made in the previous paper (Hartveit,
1962) that living Ehrlich ascites carcinoma was used in combination with Freund's
adjuvant can be upheld.
The findings here show that the tumour cells in the adjuvant mixture continue
to grow in the absence ofa further source oftumour. In the previous experiment
(Hartveit, 1962) it was found that the tumour cells in the same adjuvant mixture
did not grow in the presence of intraperitoneal tumour. This rules out the
prophylactic use of such a mixture while, at the same time, it indicates that the
mixture may be of some use in the treatment of a tumour-bearing host.
It is of note that there was a marked sex difference in the survival time in
both groups. This is contrary to the author's findings with interaperitoneal
tumour (Hartveit, 1961a), and contrary to the general experience of the intra-
peritoneal growth of this tumour. It is likely that the rapid intraperitoneal
growth rate prevents the sex difference, which becomes apparent following the
slower subcutaneous growth, from showing up. Thus female mice, in which it
is easier to induce tumour immunity (Gross, 1943), also have a greater natural
immunity to the Ehrlich ascites carcinoma than male animals.
(b) The Non-specific Action of Freund's Adjuvant on Ehrlich's Ascites Carcinoma
In the course ofthe main experiment (Hartveit, 1962) it was found that female
mice given a subcutaneous injection of Freund's adjuvant alone on the same day
as an intraperitoneal injection of Ehrlich's ascites carcinoma showed a decrease
in survival time and an increase in the blood content of their tumours when
compared to male mice given the same treatment. This reaction must be con-
sidered to be non-specific in contrast to that produced by the subcutaneous injec-
tion of Freund's adjuvant plus living tumour. It is suggested in the above
mentioned paper that the latter reaction is mediated through the same channels
as that due to natural immunity, while the former clearly operates in a different
way. It was also found that the female mice showed a marked reaction at the
subcutaneous injection site while this was absent in the males.
The sex differences in the responses mentioned above were highly significant
statistically. It was decided to follow up these findings to see if a time interval
between the injection ofthe subcutaneous adjuvant and that ofthe intraperitoneal
tumour would affect the reactions. A new experiment was, therefore, undertaken
in which mice that hadreceived Freund's adjuvant and saline subcutaneously were
given intraperitoneal tumour 30 days later, instead of on the same day as in the
main experiment (Hartveit, 1962).
Material and methods
The reader is referred to the previous paper (Hartveit, 1962) and to Table I
ofthis paper for details. To summarize: There were 15 male and 15 female mice
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in each group. Group I was the untreated control group while group 4 received
Freund's adjuvant subcutaneously. Thirty days after the mice in group 4 had
been injected with adjuvant all the mice in both groups were given an intra-
peritoneal injection of 0-1 ml. of Ehrlich's ascites carcinoma (2,300,000 tumour
cells/c.mm.). This tumour was taken from a mouse of the 87th transplant
generation. The tumour used in the previous experiment had come from the
84th transplant generation of the same tumour.
At the time of the injection of the intraperitoneal tumour the subcutaneous
swellings (approximately 0 5 cm. diameter), that had appeared within 14 days of
the injection of the adjuvant mixture in the females, persisted in all cases. In
the males the site was difficult to locate.
When the mice died the survival time was recorded in days and the blood
content of the tumour recorded after centrifugation, as described in the previous
paper (Hartveit, 1962). The subcutaneous injection site was examined at
autopsy in group 4.
Results
Table III shows the mean survival time (days), plus the SD of the mean, of
the mice in both groups. The female mice in the experimental group 4 showed
little difference in survival time from those in the control group 1. On the other
hand, there was a marked difference in the survival time ofthe male mice; those
in group 4 dying before the controls (13.64 and 17*4 days, respectively). This
difference is statistically significant (0.05>P>0-02).
TABLE III.-The Mean Survival Time (Days), plus SD, of Mice given Intra-
peritoneal Ehrlich's Ascites Carcinoma 30 days after Subcutaneous Freund's
Adjuvant (Group 1) and of Controls lacking Subcutaneous Adjuvant (Group 4)
Number Mean survival
Group Sex of mice time SD
1 . (3C . 15 . 17-4 . 6-332
r° . 15 . 12-3 . 3 194
4 . . 14* . 13-64 . 2-811
y . 15 . 12-6 . 4- 775
* One mouse accidentally killed.
Table IV gives the mean blood content of the tumour (per cent), plus the SD
ofthe mean, in both groups. Once again there is little difference in the results in
female mice, while the blood content in the males in the experimental group 4 is
TABLE IV.-The Mean Blood Content (per cent), Plus SD, of the
Intraperitoneal Tumour in Groups 1 and 4
Number Mean blood
Group Sex of mice content SD
1 . . 14t . 3 143 . 2-530
15 . 5-2 . 4-651
4 C6T . 13*t . 5 0 . 2-037
y . 15 . 5-266 . 3-347
* One mouse accidentally killed.
t Tumour unsuitable for investigation in one mouse.
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much higher than in the controls (5 and 3-14 per cent, respectively). This differ-
ence is significant statistically (0O05>P>02).
Table V shows the correlation between the survival time and the tumour
blood content (correlation coefficient, r) for both sexes in both groups. While
the negative correlation is high in the females in both groups, it is much lower in
the males in group 4 than in group 1.
TABLE V.-The Correlation between Survival Time and Tumour Blood Content
in Groups 1 and 4, using the Correlation Coefficient r
Number
Group Sex of mice r
1 . .3* lo4t . -0°5163
15 -0 8501
4 . . 13*t . -0 1642
15 -0 8027
* One mouse accidentally killed.
t Tumour unsuitable for investigation in one mouse.
At autopsy the subcutaneous injection site was easily located in 14 out ofthe
15 females as the subcutaneous swelling had persisted. It could not be detected
macroscopically in the males.
Discussion
It haspreviously been shownthatthe survivaltimeofmicewithintraperitoneal
Ehrlich ascites carcinoma is shorter in those that show a sensitivity reaction to
the tumour, and that the blood content ofthe tumour ascites is a measure ofthis
reaction, which is probably one of rejection of the foreign tumour protein (Hart-
veit, 1961b). Thus it provides a measure of the animal's natural immunity to
the tumour. In addition there is also evidence that it can be used to measure
acquired immunity (Hartveit, 1962).
In the latter experiment it was found that female mice showed this immunity
reaction if they were given a subcutaneous injection of Freund's adjuvant with-
out antigen on the same day as the intraperitoneal injection of Ehrlich's ascites
carcinoma. This was unexpected as Freund (1956) clearly states that, " the
adjuvant remains without effect if injected into a separate area ", i.e. if antigen
is not combined with adjuvant. On the other hand, Voisin, Toullet and Maurer
(1958) have reported non-specific testicular lesions following the use of adjuvant
alone.
In the present experiment the adjuvant that was given subcutaneously in
group 4 was the same as that used in group 7 of the main experiment (i.e. the mice
that received subcutaneous adjuvant on the same day as they were given intra-
peritoneal tumour). The tumour used was taken from the same source 3 trans-
plant generations later. Thus conditions in the two experiments are strictly
comparable-the time limit between the subcutaneous and intraperitoneal
injections being the determining factor.
The results show that it is now the male animals that are responding to the
adjuvant injection-the females reacting in the same way as the controls. The
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mean survival time ofthe males is now significantly less than that ofthe control
males (13.64 days compared to 17*4 days), and the blood content oftheir tumours
greater (5 per cent compared to 3*14 per cent). In addition the degree ofcorrela-
tion between the survival time and the tumour blood content is greatly reduced
(-0-1642 compared to -0.5163). The subcutaneous injection sites did not show
any change.
The mean survival time ofthe females, the blood content oftheir tumours and
the degree of correlation between these two factors now appears to be unchanged
by the treatment.
These results show that the time interval in this case was important to the
response of the mice. The immune reaction of the females developed shortly
after the injection ofthe adjuvant, while that of the males became evident later.
Inthemainpaper (Hartveit, 1962)itwas suggestedthatthereactioninthefemales
differed in mechanism from that due to natural immunity or immunity acquired
after the subcutaneous injection of Freund's adjuvant and living Ehrlich ascites
carcinoma, as the negative correlation between the survival time and the tumour
blood content, that is normally found in these mice, was upset by the treatment.
The present results support this idea as once more the animals responding to the
subcutaneous injection ofadjuvant alone (now only the males) show the same lack
of correlation between these two factors. The experiment also shows that the
immune reaction is not dependent on the reaction at the subcutaneous injection
site.
(c) Haemolysis intheEhrlich Ascites Carcinomafollowing theSubcutaneous Injection
of Whole Tumour Fluid plus Freund's Adjuvant
In the course of the analysis of the results of the main experiment (Hartveit,
1962) and of part (b) of this paper, it came to light that there were marked
differences in the amount of haemolysis in the ascitic fluid in the various groups.
These findings will now be presented in detail.
Material and methods
For a full description ofthese the reader is referred to the original paper (Hart-
veit, 1962), and to part (b) and Table I ofthis paper. To summarize: Allgroups
contained 15 male and 15 female mice. The experimental group 6 was given a
mixture ofFreund's adjuvant andliving Ehrlich ascites carcinomasubcutaneously,
while groups 1 and 2 had no subcutaneous treatment. Groups 4 and 7 were given
subcutaneous adjuvant minus tumour; group 8 subcutaneous tumour alone.
On the first day ofthe experiment the mice in groups 2, 6, 7 and 8 each received
intraperitoneal Ehrlich ascites carcinoma. Thirty days later groups 1 and 4 were
given intraperitoneal tumour. The remaining groups are not concerned in this
experiment.
When the mice died the tumour ascites was removed and centrifuged as des-
cribed previously. After centrifugation the haemolysis in the supernatant fluid
was graded:
0 = absent, pale yellow supernate.
+ = present, pink supernate.
++ = marked, dark red supernate.
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Results
The findings in both the males and the females are given in Table VI which
shows that ++ haemolysis occurred only in groups 6, 7 and 4 (in 30 per cent,
3*3 per cent and 3*6 per cent respectively). The difference in this percentage
between group 6 and the untreated mice (group 2) is highly significant statistically
(001>P>0001). There were no marked sex differences.
TABLE VI.-Haemolysis in the Ascitic Fluid of Mice with Intraperitoneal Ehrlich
Ascites Carcinoma (EAC) following the Subcutaneous Injection of Living
EAC plus Freund's Adjuvant (FA), and in Control Groups. (30 Mice in
Each Group)
Haemolysis+
Group Treatment Sex 0 + ++ %++
2 . Nil . . 10 5 0 0
y . 10 5 0O
6 . EAC + FA CT 8 3 4 30
? 8~~ 2 5j
7 . FA . C 12 3 O}
? ~11 3 if
8 . EAC . . 12 3 0O 0
? . 11 4 0O
1q . Nil . ,t 1 3 0\ 0
? . 12 3 OJ
4t . FA . 11 2 0 3*6 y 12 2 1J
* One mouse accidentally killed.
t Tumour unsuitable for investigation in one mouse.
+ For details of scale see text.
+ For details see part b.
Discussion
It was decided to ignore + haemolysis as the time that elapsed between the
death of the mouse and the centrifugation of the tumour ascites could not be
determined accurately; differences of up to 18 hr. might have occurred. It was
thought, however, that gross changes, i.e. ++ haemolysis, were unlikely to have
been brought aboutinthis way-andwere aslikely to occurin allgroups concerned
on this basis.
It was found that this degree of haemolysis was virtually confined to mice in
group 6, that is to say to the mice that had been given tumour plus adjuvant
subcutaneously. The tumour used for injection consisted of whole ascitic fluid.
No attempt was made to remove the erythrocytes, which gave a PCV of 1 per
cent Wintrobe, as such a procedure might have been detrimental to the tumour
cells. Therefore the tumour adjuvant mixture also contained erythrocytes.
The results of the experiment suggest that the combination of erythrocyte-
adjuvant may have been the cause ofthe increased haemolysis in the experimental
group. It did not occur following the administration ofwhole ascitic fluid alone,
i.e. tumour, erythrocytes and ascitic serum (group 8), and there was only a veryF. HARTVEIT
minor non-specific reaction following subcutaneous adjuvant alone. It was also
absent in the untreated controls.
Considering these findings in relation to those in the main experiment (Hart-
veit, 1962) it could be argued that it was this haemolysis that was detrimental
to the mice in the experimental group, and that it was this, and not a reaction
against the tumour protein, that played a major part in their early death. If
only the survival time is considered this appears quite possible, but when taken
in conjunction with the tumour blood content it is evident that this is unlikely.
While one could well expect treatment with an erythrocyte-adjuvant mixture
to increase the haemolysis of the blood present in the tumour, one could hardly
expect that to account for an increase in the blood content itself.
Secondly it could be argued that group 6 showed the greatest amount of
haemolysis as the tumours contained the greatest amounts of blood. However,
on referring back to Table III of the original paper (Hartveit, 1962) it will be
seen that the females in group 7 showed almost as high a tumour blood content
as those in group 6, while they do not show a correspondingly high degree of
haemolysis.
Thus the haemolysis will have detracted from the findings on the blood content
of the tumour ascites in group 6 as judged from the packed cell volume of the
erythrocytes present. The amount of blood present was, in fact, even greater
than that recorded in this group. It is of note that this reaction to a normal
tissue did not show a sex difference while that related to the tumour tissue did.
SUMMARY
(a) Emulsification of Ehrlich's ascites carcinoma with Freund's adjuvant does
not appear to have adversely effected the growth ofthe tumour cells in the mixture
when this is injected subcutaneously into healthy mice. On subcutaneous injec-
tion ofthe tumour the female mice show greater natural immunity than the males
as evidenced by their longer survival time.
(b) A non-specific immune type reaction to Ehrlich's ascites carcinoma was
found in male mice following the subcutaneous injection of Freund's adjuvant
mixture 30 days before the intraperitoneal injection ofEhrlich's ascites carcinoma.
Female mice showed no reaction after this time interval, and the time interval had
no effect on the reaction at the site of the subcutaneous adjuvant injection.
Further the immune reaction was not dependent on the latter. While the
mechanism of the immune reaction is thought to be similar to that occurring in
female mice when the adjuvant is given on the same day as the tumour, it is
suggested that it differs from that accompanying natural immunity and from the
immunity acquired after the subcutaneous injection of Freund's adjuvant plus
living tumour.
(c) It was found that haemolysis occurred in intraperitoneal Ehrlich ascites
carcinoma following the subcutaneous injection ofwhole Ehrlich ascites carcinoma
plus Freund's adjuvant. Marked haemolysis was absent in the untreated control
groups. This haemolysis is thought to have been due to the erythrocytes present
in the ascitic tumour fluid that was combined with the adjuvant mixture. The
haemolysis will have detracted from the findings in the main experiment; the
haemorrhagic response to the intraperitoneal tumour following the subcutaneous
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injection of tumour plus adjuvant being in fact greater than that given by the
PCV of the erythrocytes.
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